18 December 2024NewsAmericasMithu Sherin Director of Intellectual Property ALX Oncology, David Diamond VP & Head of Intellectual Property Capstan Therapeutics, Alexander Trimble Member Mintz, Siegmund Gutman Chair Life Sciences Litigation Practice Mintz

WATCH: Beyond the obvious: novelty, non-obviousness, and the inventive step in polymorph patents and beyond

In the world of intellectual property, securing patents for innovative ideas rests heavily on the criteria of novelty, non-obviousness, and the inventive step. This panel will examine the complexities of these fundamental patent requirements in practice, with a special focus on polymorph patents and related areas. We'll explore how recent developments and legal decisions impact innovators and the IP landscape. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.